Norfloxacin Capsules

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial activity against the following bacteria in vitro: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes and other Enterobacter species, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. Norfloxacin also has antibacterial activity against multi-drug resistant bacteria in vitro. It also has good antibacterial effects on penicillin-resistant Neisseria gonorrhoeae, Haemophilus influenzae and Moraxella catarrhalis. Norfloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

Norfloxacin

It is suitable for urinary tract infections, gonorrhea, prostatitis, intestinal infections, typhoid fever and other Salmonella infections caused by sensitive bacteria.

Oral. 1. Acute simple lower urinary tract infection caused by Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: 400 mg (4 tablets) once, twice a day, for a course of 3 days. 2. Simple urinary tract infection caused by other pathogens: the same dosage as above, for a course of 7-10 days. 3. Complicated urinary tract infection: the same dosage as above, for a course of 10-21 days. 4. Simple gonococcal urethritis: 800-1200 mg (8-12 tablets) once. 5. Acute and chronic prostatitis: 400 mg (4 tablets) once, twice a day, for a course of 28 days. 6. Intestinal infection: 300-400 mg (3-4 tablets) once, twice a day, for a course of 5-7 days. 7. Typhoid Salmonella infection: 800-1200 mg (8-12 tablets) a day, divided into 2-3 doses, for a course of 14-21 days.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions include rash, skin itching, and occasionally exudative erythema multiforme and angioedema. A small number of patients have photosensitivity reactions. 4. Occasionally, the following may occur: (1) Epileptic seizures, mental abnormalities, irritability, impaired consciousness, hallucinations, and tremors. (2) Manifestations of interstitial nephritis such as hematuria, fever, and rash. (3) Phlebitis. (4) Crystalluria, which is more common when used in high doses. (5) Joint pain. 5. A small number of patients may experience elevated serum aminotransferases, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients who are allergic to this product and fluoroquinolones are contraindicated.

Precautions for children: The safety of this product in infants and adolescents under 18 years of age has not been established. However, this product can cause joint lesions when used in several young animals. This product should not be used in children and adolescents under 18 years of age. Precautions for pregnancy and lactation: Reproduction studies have been conducted with monkeys, with doses as high as 10 times the human dose, and it was found that this product can cause abortion. The peak plasma concentration (Cmax) of this dose in monkeys is about twice that of humans. This product has not been proven to be teratogenic in animals. However, no appropriate and well-controlled studies have been conducted in pregnant women, so this product should not be used in pregnant women. There is still a lack of information on whether this product is secreted through breast milk. When a lactating woman uses 200 mg of this product, the drug cannot be detected in breast milk. However, due to the small study dose, and the fact that other varieties of this class of drugs are secreted through breast milk, coupled with the potential serious adverse reactions to newborns and infants, lactating women should avoid using this product or stop breastfeeding when using it. Precautions for the elderly: Elderly patients often have impaired renal function, and because this product is partially excreted through the kidneys, it needs to be used in a reduced dose.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When this product is used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver clearance of theophylline, a prolonged blood elimination half-life (t1/2β), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, theophylline blood drug concentration should be measured and the dose adjusted when used in combination. 3. Cyclosporine combined with this product can increase the blood drug concentration of the former. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4. This product can enhance the anticoagulant effect of the latter when used with the anticoagulant warfarin. The patient's prothrombin time should be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6. This product has an antagonistic effect with nitrofurantoin, and its combined use is not recommended. 7. Multivitamins, or other preparations containing iron or zinc ions, and antacids containing aluminum or magnesium can reduce the absorption of this product. It is recommended to avoid co-use. If it cannot be avoided, take it 2 hours before or 6 hours after taking this product. 8. Didanosine (DDI) can reduce the oral absorption of this product. Because its preparation contains aluminum and magnesium, it can chelate with fluoroquinolones, so it is not suitable for co-use. 9. This product interferes with the metabolism of caffeine, resulting in reduced caffeine clearance, prolonged blood elimination half-life (t1/2β), and possible central nervous system toxicity.

[02] Cool storage area for medicines (below 20°C)

0.1 g

12 months